Acalabrutinib
Small molecule
Also known as ACP-196
Evidence outlook
Approved: Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Diffuse Large B-Cell Lymphoma · Phase 3 · investigational in the US
Also approved (2)
- Treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
- Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.Calquence in combination with bendamustine and rituximab (BR) is indicated for the...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ElevateTN NCT02475681 · Chronic Lymphocytic Leukemia This was a randomized phase 3 trial of 535 people with an active comparator and a hard progression-free survival endpoint that was clearly met. Only outcome assessors were masked and treatment was open-label, so it is graded below the highest tier. Registry: NCT02475681 | 3 | Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B (IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.) 2019-02-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 3 more trials
NCT02970318 NCT02970318 · Chronic Lymphocytic Leukemia This was a randomized phase 3 trial of 310 people against an active comparator with a hard progression-free survival endpoint that was clearly met. Treatment was open-label with only outcome assessors masked, so it is graded below the highest tier. Registry: NCT02970318 | 3 | Progression-free Survival (PFS) Per Independent Review Committee (IRC) Assessment (IRC assessments from randomization date until disease progression or death or IRC discontinuation on 15Jan2019 (as IA per this data cutoff showed crossing superiority boundary) whichever came first, up to 22 months of follow-up) 2021-09-03 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02477696 NCT02477696 · Chronic Lymphocytic Leukemia This was a randomized phase 3 non-inferiority trial of 533 people against an active comparator (ibrutinib) with a hard progression-free survival endpoint. The prespecified non-inferiority margin was met, but only outcome assessors were masked and treatment was open-label. Registry: NCT02477696 | 3 | Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)) 2020-09-15 | Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment (Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)): Acalabrutinib 38.4 Months (95% CI 33 to 38.6) | Ibrutinib 38.4 Months (95% CI 33 to 41.6) | Partial signal | link ↗ |
AMPLIFY NCT03836261 · Chronic Lymphocytic Leukemia Patients were randomized to acalabrutinib combinations or standard chemoimmunotherapy, and the primary endpoint, progression-free survival read by a blinded independent central reviewer, improved significantly with acalabrutinib-venetoclax. Patients and doctors knew which treatment was given, which keeps this from the highest grade even though the endpoint was read independently. Registry: NCT03836261 | 3 | To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared to chemoimmunotherapy fludarabine/cyclophosphamide/rituximab [FCR] or bendamustine/rituximab [BR] (Arm C): PFS (6 years) 2027-04-30 | In progress: results expected 30 Apr 2027 | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (79)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (29)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (4)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (2)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other BTK drugs
Ibrutinib, Pirtobrutinib, rilzabrutinib, zanubrutinib. Compare all 5 BTK drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Mantle Cell Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Acalabrutinib: this drug | Approved | Small molecule | BTK | Weak signal | NCT02213926: Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) in Subjects With Previously Treated MCL. (From the date of the first dose until 30 days after the last dose of the study drug or start of a new anti-cancer treatment, whichever came first, assessed up to approximately 4 year and 10 months. 1 cycle =28 days): ACP-196 (Acalabrutinib) — CR: 59 Participants; PR: 42 Participants; SD: 10 Participants; PD: 10 Participants; NE: 3 Participants | |
| Bortezomib | Approved | Small molecule | Proteasome | not yet graded | No reviewed efficacy summary in this indication | |
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | not yet graded | No reviewed efficacy summary in this indication | |
| Pirtobrutinib | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Rilzabrutinib | Approved(overall) | Small molecule | BTK | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Sonrotoclax (Beqalzi) | Approved | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| Zanubrutinib (Brukinsa) | Approved | Small molecule | BTK | Weak signal | NCT04002297: Primary endpoint, progression-free survival: zanubrutinib plus rituximab superior to bendamustine plus rituximab (BeOne topline, 2026-06-01). NCT03206970: Overall response rate by independent review: 72/86 (83.7%, 95% CI 74.2 to 90.8), p<0.0001 against a null rate of 40% (single arm) (CT.gov posted results). | |
| Ibrutinib | Phase 3 | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Mesutoclax | Phase 3 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(57 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Acalabrutinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (26)
January 2027 (4)
What to watch
What to watch
What to watch
What to watch
February 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (2)
September 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (15)
February 2028 (1)
What to watch
March 2028 (3)
What to watch
What to watch
What to watch
May 2028 (1)
What to watch
June 2028 (2)
July 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (2)
2029 (7)
January 2029 (2)
What to watch
What to watch
February 2029 (1)
What to watch
April 2029 (2)
May 2029 (1)
What to watch
July 2029 (1)
2030 (1)
May 2030 (1)
What to watch
2032 (1)
September 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent